STOK (Stoke Therapeutics) GF Value : $0.00 (As of Dec. 15, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics GF Value?

As of today (2024-12-15), Stoke Therapeutics's share price is $12.06. Stoke Therapeutics's GF Value is $0.00. Therefore, Stoke Therapeutics's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Stoke Therapeutics is Not Valued.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

Stoke Therapeutics (NAS:STOK) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Stoke Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	12.06	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stoke Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Executives

Barry Ticho	officer: Chief Medical Officer	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Skorpios Trust	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Huw M. Nash	officer: COO & CBO	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Jonathan Allan	officer: General Counsel & Corp Sec	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Kaye Edward M. Md	director, officer: CEO	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Stephen J Tulipano	officer: CFO	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Atp Life Science Ventures, L.p.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Montrago Trustees Ltd	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau	officer: EVP Research & Preclinical Dev	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin	director	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Arthur Tzianabos	director	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730